KR20150045420A - Composition for blocking AGEs production comprising Akebia quinata extracts - Google Patents

Abstract

The present invention relates to a composition for skin external application that inhibits the production of advanced glycation end products (AGEs), wherein the compositions comprise as active ingredients one or more of the extracts from fruits and branches of Akebia quinata. Specifically, the composition of the present invention has mitigating effects on skin wrinkles through the mechanism in which the composition prevents fibroblasts from cell damage by inhibiting the production of AGEs. Also, the composition has no cytotoxicity and no side effects on the skin, thus being safely applicable in cosmetics or pharmaceutical products.

Description

(AGEs) production inhibiting composition for inhibiting the production of AGEs containing an extract of Aspergillus oryzae as an active ingredient.

The present invention relates to a composition for external application for skin comprising an extract of Aspergillus oryzae as an active ingredient. More specifically, the present invention relates to a composition for inhibiting ultimate glycation endogenous activity, The present invention relates to a composition for external application for skin.

 Glycation is a nonenzymatic reaction between sugars and proteins that reacts with the carbonyl of the reducing sugar and the free amino group lysine or arginine of the protein to form the schiff base, , And the compounds thus formed are continuously reacted to generate advanced glycation end products (AGEs), which are browning compounds through a series of reactions such as cross-linking.

Specifically, in the normal state, the sugar and the protein undergo a Millard reaction, which is a non-enzymatic reaction to form a schiff base and rearranged to form amadori early glycosylation products The reaction up to here occurs reversibly and its concentration is controlled. However, when the hyperglycemic state persists, the reversible amaryllis type early glycation products are rearranged without degradation, cross-linking with long-lived proteins, resulting in irreversible final glycation products (Ulrich P et al., Recent Prog Horm Res 56; 1-21: 2001). The resulting final glycation products are known to cross-link with extracellular matrix proteins or to react with the final glycated product receptors or nucleic acids of body cells (endothelial cells, smooth muscle, immune cells, etc.) to induce diabetic complications. Therefore, many researches have been conducted to find a pharmacologically active substance which inhibits the glycation reaction that produces the final glycation endproduct to prevent diabetic complications.

In addition, the glycation reaction occurs rapidly in diabetic patients having hyperglycemia, but the glycation reaction occurs in normal persons having normal blood sugar as the aging progresses. Typically, it is known that cross-linking with collagen results in the accumulation of the final glycation products in the skin, which leads to skin elasticity reduction and wrinkles. The half-life of these final glycation products is two times Which is known to induce damage to skin cells such as fibroblasts. In addition, it has been reported that abnormal lipid metabolism occurs during the production of a final saccharide product and oxidative stress is induced due to deterioration of the defensive system function against harmful oxygen free radicals generated at the same time. This is caused by Alzheimer's disease, Aging Medicine, 8 (3) (2001), pp. 183-190, 1986. In the present study, : 23-29, 2011; Reddy VP et al., Neurotox Res 4; 191-209: 2002; Fuentealba D et al., Photochem Photobiol. 85 (1): 185-94, 2009).

In order to prevent diabetes, skin wrinkles, cellular damage, and chronic diseases caused by the final glycation end product, it has been proposed to use carnosine, benfotiamine, pyridoxamine, taurine ), Aminoguanidine, aspirin, and the like. However, aminoguanidine was stopped due to toxicity related to vitamin B deficiency in Phase III clinical trials. In the case of pyridoxamine, the drug has not yet been commercialized as it is currently undergoing phase 2 clinical trials and is in phase 3 preparations.

On the other hand, Korean Patent No. 1081910 discloses a cosmetic composition having an effect of improving skin tone and preventing skin aging, which contains kiwifruit extract as an active ingredient, as a technique related to inhibition of final glycation endogenous production, and Korean Patent No. 0997912 Korean Patent No. 0973941 discloses a composition for the treatment and prevention of diabetic complications and a functional food using the extract of Zanthoxylumbel, .

However, as yet to the present invention, the effect on the inhibition of final glycation endogenesis by Crane extract is not disclosed.

Accordingly, the present inventors have made efforts to develop a composition for external application for skin which is harmless to the human body and has excellent safety, but has the effect of inhibiting the final glycation products, using the Aspergillus oryzae extract. As a result, it is possible to inhibit the production of the final glycation end product, And the present invention has been completed.

One object of the present invention is the use of Akebia < RTI ID = 0.0 > quinata extract as an active ingredient. The present invention also provides a composition for preventing external skin glycosylation.

Another object of the present invention is to provide the use of the composition for external skin application for inhibiting the final glycation end product formation.

As one embodiment, the present invention provides a cosmetic composition for improving the skin condition selected from the group consisting of skin wrinkle improvement, skin elasticity improvement, skin aging prevention, and skin regeneration by inhibiting the production of a final glycation product, The present invention relates to a cosmetic composition for improving the skin condition comprising an extract of Akebia quinata as an active ingredient.

In the present invention, Akebiae quinata Decne ) is a deciduous vine plant belonging to the genus Liliaceae , and grows in all parts of the country. In one tree, female flowers and male flowers are used separately for different ornamental purposes. In addition, young leaves and fruit are used for edible, root and branch medicinal purposes. Specifically, the sprouts and young stems were eaten as herbs, and the flowers were dried and used instead of perfume. Stem boiled water was used as a yellow or yellowish dye, and was especially important for medicinal use because it has efficacy for anti-inflammatory diuretics, urinalysis, urethritis, sore throat, and psychotropic drugs. Roots and bark are effective for urination disorders, and fruits are effective for diuretics, paralysis, and arthritis.

In the present invention, the Crane extract can be obtained by using an extraction method and an extraction solvent known in the art, preferably water, an anhydrous or hydric alcohol having 1-4 carbon atoms (methanol, ethanol, propanol, butanol Etc.), a mixed solvent of the lower alcohol and water, acetone, ethyl acetate, chloroform or 1,3-butylene glycol as an extraction solvent.

In addition to the above extraction method, the vinegar extract may be obtained by a conventional purification process. For example, separation using an ultrafiltration membrane having a constant molecular weight cut-off value, separation by various chromatographies (made for separation by size, charge, hydrophobicity or affinity) Through the obtained fraction, Rhizophora japonica extract can be obtained.

In the present invention, the Crane extract contains all of the extract, fraction and purified product obtained in each step of extraction, fractionation or purification, their diluted solution, concentrate or dried product.

In the present invention, at least one selected from the fruit or branch of the mulberry can be used as the mulberry extract.

In the present invention, the inhibition of the final glycation endproduct formation is characterized by the inhibition of ultimate glycation end products which can inhibit the glycation reaction of skin cells, particularly dermal fibroblast cells.

In the present invention, improvement of at least one skin condition selected from the improvement of skin wrinkles, the improvement of skin elasticity, the prevention of aging, and the skin regeneration is induced by the inhibition of final glycation product formation.

According to the present invention, the composition for external application for skin glycosylation inhibition, which comprises the above-mentioned crane extract as an active ingredient, inhibits the production of the final glycosylation product of the skin, thereby protecting the damaged cells by the final glycosylation product. , Anti-aging and skin regeneration efficacy.

In one specific embodiment, cell viability for glycosylation and oxidative stress according to the concentration of Aspergillus niger extract using human normal fibroblast was examined. As the concentration of Aspergillus niger extract increased, the cell survival rate , And it was confirmed that the extracts of Rhodia japonica have an effect of inhibiting cell damage from the final glycation products and oxidative stress.

In another specific embodiment, the skin elasticity of the human skin was examined using a cosmetic composition containing a myrtle extract. As a result, the skin elasticity of the cosmetic composition containing the myrtle extract was significantly higher than that of the cosmetic composition containing no myrtle extract And it was confirmed that the vinegar extract had an effect of improving wrinkles.

In the present invention, the myrtle extract is contained in an amount of 0.00001 to 15% by weight, preferably 0.0001 to 10% by weight, more preferably 0.001 to 5% by weight, based on the total weight of the whole composition. When the weight of the vinegar extract is less than 0.0001% by weight, the effect of inhibiting the final glycation end product is too weak. When the weight of the vinegar extract is more than 15% by weight, the effect of increasing the content of the vinegar extract is insufficient.

In the present invention, the composition of the present invention can be used as a cosmetic composition for external skin application for inhibiting ultimate glycation products, comprising an extract of Aspergillus oryzae as an active ingredient.

The extraction method and the efficacy of the crude extract of the present invention are as described above.

The cosmetic composition according to the present invention may further comprise components commonly used in cosmetic compositions, in addition to the composition for inhibiting ultimate glycation products, which comprises an extract of Aspergillus oryzae as an active ingredient. For example, conventional adjuvants such as antioxidants, stabilizers, solubilizers, vitamins, pigments and flavoring agents, and carriers may be included.

The cosmetic composition may be prepared in any form conventionally produced in the art and may be in the form of, for example, a solution, suspension, emulsion, paste, gel, cream, lotion, powder, soap, surfactant- , A powder foundation, an emulsion foundation, a wax foundation, and a spray, but the present invention is not limited thereto. More specifically, it can be prepared as a nutritional cream, a convergent lotion, a soft lotion, a lotion, an essence, a nutritional gel or a massage cream.

When the formulation of the cosmetic composition is a paste, a cream or a gel, the carrier component may be an animal oil, vegetable oil, wax, paraffin, starch, tragacanth gum, cellulose derivative, polyethylene glycol, silicone, bentonite, silica, talc or zinc oxide Can be used.

When the formulation of the cosmetic composition is a powder or a spray, lactose, talc, silica, aluminum hydroxide, calcium silicate or polyamide powder may be used as a carrier component. In particular, in the case of spray, a mixture of chlorofluorohydrocarbons, Propellants such as propane / butane or dimethyl ether.

In the case of the solution or emulsion of the cosmetic composition, a solvent, a solubilizer or an emulsifier is used as a carrier component. Examples of the solvent include water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, , 3-butylene glycol, a glycerol aliphatic ester, a polyethylene glycol, or a fatty acid ester of sorbitan can be used as a solubilizing agent or an emulsifying agent.

When the formulation of the cosmetic composition is in the form of a suspension, the carrier component may be a liquid diluent such as water, ethanol or propylene glycol, a suspending agent such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester, Cellulose, aluminum metahydroxide, bentonite, agar or tragacanth gum may be used.

When the formulation of the cosmetic composition is an interfacial active agent-containing cleansing agent, it is preferable to use, as carrier components, aliphatic alcohol sulfates, aliphatic alcohol ether sulfates, sulfosuccinic acid monoesters, isethionates, imidazolinium derivatives, methyltaurate, sarcosinates, fatty acids Amide ether sulfate, alkylamidobetaine, aliphatic alcohol, fatty acid glyceride, fatty acid diethanolamide, vegetable oil, lanolin derivative, or ethoxylated glycerol fatty acid ester.

The myrtle extract is contained in an amount of 0.00001 to 15% by weight, preferably 0.0001 to 10% by weight, more preferably 0.001 to 5% by weight based on the total weight of the whole composition. When the weight of the vinegar extract is less than 0.0001% by weight, the effect of inhibiting the final glycation end product is too weak. When the weight of the vinegar extract is more than 15% by weight, the effect of increasing the content of the vinegar extract is insufficient.

In the present invention, the composition may be used as a composition for external dermal application for inhibiting ultimate glycation products, which comprises an extract of Aspergillus oryzae as an active ingredient.

The extraction method and the efficacy of the crude extract of the present invention are as described above.

The pharmaceutical composition according to the present invention may further comprise components commonly used in pharmaceutical compositions, in addition to the composition for inhibiting the final glycation endproduct containing the extract of Aspergillus oryzae as an active ingredient. For example, lubricants, wetting agents, sweeteners, flavoring agents, emulsifying agents, suspending agents, preservatives and carriers.

Suitable carriers for such pharmaceutical compositions include, but are not limited to, lactose, dextrose, sucrose, sorbitol, mannitol, starch, acacia, calcium phosphate, alginate, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, Syrup, methyl cellulose, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil, but are not limited thereto. Carriers and preparations which are acceptable as suitable medicaments are described in detail, for example, in Remington's Pharmaceutical Sciences (19th ed., 1995).

The pharmaceutical composition may be applied to mammals such as rats, mice, livestock, humans, etc. by oral or parenteral administration, and is preferably administered by parenteral administration, more preferably topical application by application .

The pharmaceutical composition is administered in a medically effective amount. A therapeutically effective amount in the present invention means an amount sufficient to treat or prevent a disease at a reasonable benefit / risk ratio applicable to medical treatment or prevention. The effective dose level will depend on the type of disease and its severity, the activity of the drug, Including the age, weight, health and sex of the patient, sensitivity of the patient to the drug, time of administration of the particular extract used, route of administration and rate of release, duration of treatment, Can be determined according to factors well known in the art. Generally, a dose of 0.001 to 100 mg / kg, preferably 10 to 100 mg / kg on an adult basis can be administered once to several times per day. When the composition is an external preparation, it is preferable to apply the composition in an amount of 1.0 to 3.0 ml on an adult basis once to five times a day and continue for 1 month or more. However, the scope of the present invention is not limited by the dose.

The pharmaceutical composition may be prepared in a unit dosage form by formulating it together with a pharmaceutically acceptable carrier and / or excipient according to a method which can be easily carried out by a person skilled in the art to which the present invention belongs, Into the container. The formulations may be formulated into tablets, capsules, powders, granules, suspensions, emulsions, syrups, emulsions, alerts, ointments, sprayers, oils A tablet, a tincture, a bath, a liniment, a lotion, a patch, a pad, a cream, and the like. In addition, it can be preferably used as an external preparation for skin intended for topical administration for application directly to the affected area. In this case, a form such as an ointment, a lotion, a spray or a gel is preferable. These external preparations for skin may also be included in a support base or matrix or the like, which can be applied directly to the treatment site, and examples of the support substrate include gauze or bandages.

The myrtle extract is contained in an amount of 0.00001 to 15% by weight, preferably 0.0001 to 10% by weight, more preferably 0.001 to 5% by weight based on the total weight of the whole composition. When the weight of the vinegar extract is less than 0.0001% by weight, the effect of inhibiting the final glycation end product is too weak. When the weight of the vinegar extract is more than 15% by weight, the effect of increasing the content of the vinegar extract is insufficient.

The composition for external skin application for inhibiting the formation of a final glycation end product, which comprises the extract of Aspergillus oryzae according to the present invention as an active ingredient, inhibits the production of the final glycation end product and inhibits the production of the final glycation end product, thereby improving skin wrinkles and skin elasticity , Skin aging prevention, and skin regeneration. And can be safely applied to cosmetics or medicines without cytotoxicity and skin side effects.

FIG. 1 shows the result of measuring the inhibitory effect of the final glycation end product according to the concentration of the crane extract of the present invention.
FIG. 2 shows the results of measuring the fibroblast-protecting effect from glycosidation stress according to the concentration of the mulberry extract of the present invention.
FIG. 3 shows the results of measuring the protective effect of fibroblasts on the oxidative stress according to the concentration of the extract of Vinegar of the present invention.

Hereinafter, the present invention will be described in more detail with reference to Examples. These embodiments are only for describing the present invention more specifically, and the scope of the present invention is not limited by these embodiments in accordance with the gist of the present invention.

Example  1: Manufacture of Crane Vine Extract

The fruits and branches of the vine were collected and washed thoroughly to remove impurities and impurities completely, shaken at 20 to 35 ° C respectively, and pulverized to have a particle size of 1 mm or less. Then, 500 g of the ground crushed vine nut and egg yolk powder was immersed in 5 L of 95% methanol and sonicated for 24 hours. Thereafter, the obtained extract was filtered through a filter paper (Advantes, No. 2) and concentrated under reduced pressure to prepare a crude myrtle extract.

Example  2: Extract of Crane Vine The final glycation product  Measurement of production inhibition effect

A glycation inhibitor assay was performed to measure the ability of the fruit and branch extracts of Crane Vine prepared in Example 1 to inhibit the production of the final glycation end product. Specifically, bovine serum albumin (BSA) was selected as a protein source. BSA was added to 0.1 M phosphate buffer (pH 7.0) to a concentration of 1 mg / ml. Glucose was used as a source of glucose and it was added to 0.1 M phosphate buffer (pH 7.0) so that the concentration of glucose was 200 mM. BSA and glucose were then added to the 1.5 ml microcube. Then, the mixture of BSA and glucose was treated with 100 and 500 ppm Crude Extract, and the mixture was completely sealed and cultured in a constant temperature and constant-humidity incubator at 60 ° C for 2 days. After the incubation, 50 쨉 l of 100% (w / v) trichloroacetic acid (TCA) was treated, left at 4 째 C for 30 minutes, and centrifuged at 15,000 rpm. After centrifugation, the supernatant was removed and 0.5 ml of PBS (Phosphate buffered saline, pH 10) was added to dissolve the precipitate. The dissolved precipitate was transferred to a 96-well microplate for fluorescence measurement and was measured at 370 nm excitation wavelength and 440 nm emission wavelength using a spectrofluorometer (INFINITE M200, Tecan, Switzerland). The control group was a mixture of BSA and glucose, and the positive control group was aminoguanidine. The results are shown in Fig.

As a result of the experiment, it was observed that the extract of Aspergillus crassifolia inhibits the production of the final glycation end product, and the inhibitory effect of the Aspergillus crassifolia extract on the final glycation end product is dose dependent. In addition, it was confirmed that the extracts of Aspergillus oryzae were superior to those of Aspergillus oryzae.

Example  3: Glycation  From stress Fibroblast  Protection effect

Human normal fibroblasts were inoculated into a 24-well microplate containing DMEM medium to a concentration of about 3 x 10 ⁴ cells and cultured in a 5% CO ₂ incubator at 37 ° C for 24 hours Lt; / RTI > Subsequently, the medium of each well was replaced with glucose-free 5% serum DMEM medium, treated with high glucose (200 mM) and 10- and 50-ppm crude vinegar extracts capable of inducing glycation stress on the cells, After re-culture, cell viability was measured using MTT assay (ATCC ^TM , 30-1010K) at the end of culture. Glucose was used as the control group, and aminoguanidine was used as the positive control group. The results are shown in Fig.

As a result of the experiment, it was shown that the extract of Aspergillus oryzae inhibited the cell death of the fibroblast induced by saccharification stress by the high glucose concentration and the inhibition rate of the cell death was increased as the concentration of the Aspergillus oryzae extract increased, . In addition, the extract of Aspergillus oryzae showed a superior cell death inhibition effect compared to the extract of Aspergillus oryzae.

Example  4: From oxidative stress Fibroblast  Protection effect

Human normal fibroblasts were inoculated into a 24-well microplate containing DMEM medium to a concentration of about 3 x 10 ⁴ cells and cultured in a 5% CO ₂ incubator at 37 ° C for 24 hours Lt; / RTI > Thereafter, the cells were exchanged with serum-free DMEM medium, treated with 10 and 50 ppmm Crassostrea japonica extract, and treated with hydrogen peroxide (H ₂ O ₂ ) at a concentration of 0.5 mM 4 hours later. Then, the cells were cultured again for 72 hours, and cell viability was measured using MTT assay (ATCC ^TM , 30-1010K) at the end of the culture. In the control group, cells treated with hydrogen peroxide (H ₂ O ₂ ) were used. The results are shown in Fig.

As a result of the experiment, it was found that the extract of Aspergillus oryzae inhibited the cell death of fibroblasts induced by hydrogen peroxide (H ₂ O ₂ ), and the inhibition rate of cell death was increased with increasing concentration of Aspergillus oryzae Respectively. In addition, the extract of Aspergillus oryzae showed a superior cytotoxic effect as compared with the extract of Aspergillus oryzae.

Example  5: Containing virgin extract Cosmetic  Wrinkle improvement effect measurement

5-1. Manufacture of cream containing vinegar extract

Nutritive creams containing vinegar extracts (fruits and branches) having the components and contents as shown in Table 1 below were prepared. Specifically, the water-purifying water, triethanolamine and propylene glycol were heated and dissolved at 70 DEG C, and then a fatty acid, an oily component, an emulsifier and an antiseptic agent were heated to 70 DEG C to dissolve. After completion of the emulsification, the solution was cooled to 45 캜, 0.1 wt% of Crassulidae extract was added and dispersed, and then cooled to 30 캜.

ingredient Content (% by weight) Vine Extract (fruit or branch) 0.1 Jojoba oil 5.0 Liquid paraffin 7.0 Cetylaryl alcohol 2.0 Polyglyceryl-3 methylglucose distearate 2.0 Glyceryl stearate 0.5 Squalane 3.0 Propylene glycol 4.0 glycerin 5.0 Triethanolamine 0.3 Carboxyvinyl polymer 0.3 Tocopheryl acetate 0.2 Preservative, incense a very small amount Purified water Balance Sum 100

5-2. Measuring wrinkle improvement effect of nourishing cream containing vinegar extract

Forty healthy women (26 to 40 years old), each containing nutrient cream containing 0.1% by weight of extract (fruit and egg plant) prepared by the method of 5-1 above, were applied to the face of the subject twice a day for 3 months Respectively. As a control group, nutritional cream prepared by adding purified water instead of crane vine extract was used.

The wrinkle improvement effect was evaluated by measurement of skin elasticity change, and skin elasticity was measured with a Cutometer SEM 474 (Courage + Khazaka, Cologne, Germany) under the condition that the temperature was maintained at 24 to 26 ° C and the humidity was constant at 38 to 40% . The comparison criteria were as follows: 0 for no skin elasticity, 5 for many cases. The results are shown in Table 2.

Classification Example 1 Control group Fruit extract Eggplant extract Skin elasticity 2.75 2.69 2.40

As shown in the above Table 1, when the nutritional cream containing the crude extract of the present invention was used, the elasticity of the skin was increased compared with the case of using the nutritional cream containing no vine extract, and the fruit extract of the perilla Of the extracts were more effective.

Example  6: Confirmation of the safety of human skin of Crane Extracts

6-1. Manufacture of external preparations for skin including vinegar extract

In order to confirm that the vinegar extract was safe for human skin, skin external preparation containing 1% by weight of Crassostrius japonica extract was prepared by the ingredients and contents shown in Table 3 below, and skin safety verification test was conducted. First, squalene was mixed with purified water, glycerin, and butylene glycol, and dissolved at a temperature of about 70 DEG C (water part). Then, the three components and the other components except for trimethanolamine were dissolved at a temperature of about 70 DEG C Part). Thereafter, the oil part was added to the water-based part, and the mixture was firstly emulsified with a homomixer (Tokushu Kika, Japan), followed by final addition of trimethanolamine.

ingredient content (%) Test group 1 Test group 2 Control group Purified water 71 71 71 glycerin 8.0 8.0 8.0 Butylene glycol 4.0 4.0 4.0 Vinegar fruit extract 0.1 0 0 Wormwood Branch Extract 0 0.1 0 Caprylic Capri Triglyceride 8.0 8.0 8.0 Squalane 5.0 5.0 5.0 Cetearyl glucide 1.5 1.5 1.5 Sorbitan stearate 0.4 0.4 0.4 Cetearyl alcohol 1.0 1.0 1.0 Trimethanolamine 0.1 0.1 0.1 Gross weight 100 100 100

6-2. Experiment of cumulative stimulation of skin

The skin external preparation prepared by the method of 6-1 was applied to 30 healthy adults for 9 times for 24 hours in total on the upper forearm to measure irritation of the skin. As a control group, squalane base was used as an external preparation for skin without vinegar extract.

A pin chamber (Finn chamber, Epitest Ltd, Finland) was used as a pellet, and 15 占 퐇 of each of the skin external preparations was dripped into the chamber and pelletized. The degree of the skin reaction on each occasion was scored using Equation 1 below, and the results are shown in Table 4 below.

[Experimental Equation 1]

Average response rate = [[Reaction index × reaction rate / total number of subjects × highest score (4 points)] × 100] / number of tests

At this time, a score of ± is given as 1, a score of 2 is given as +, and a score of 4 is given as ++, and a safe composition is determined when the average degree of reaction is less than 3.

Test substance Number of subjects who responded (persons) Average
Reactivity 1 week 2 weeks 3 weeks Primary Secondary Third Fourth 5th 6th Seventh 8th car 9th ± / + / ++ ± / + / ++ ± / + / ++ ± / + / ++ ± / + / ++ ± / + / ++ ± / + / ++ ± / + / ++ ± / + / ++ Control group 0/0/0 0/0/0 0/0/0 0/0/0 0/0/0 0/0/0 0/0/0 0/0/0 0/0/0 0.00 Test group 1 0/0/0 0/0/0 0/0/0 0/0/0 0/0/0 0/0/0 0/0/0 0/0/0 0/0/0 0.00 Test group 2 0/0/0 0/0/0 0/0/0 0/0/0 0/0/0 0/0/0 0/0/0 0/0/0 0/0/0 0.00

As shown in Table 4, the number of persons corresponding to ±, +, and ++ in the control group and the test groups 1 and 2 was 0, 0, and 0, respectively, and no skin reaction was observed. As a result of calculation according to the above-described laboratory 1, the average degree of reactivity was 0.00, 0.00 and 0.00, respectively, indicating that the composition was safe.

Manufacturing example  One : Cosmetics  Formulation

1-1. Production of flexible lotion

As shown in the following Table 5, a lotion lotion containing an extract of Crassus Vinegar as an active ingredient was prepared by a conventional method.

ingredient Content (% by weight) Vine Extract 0.1 glycerin 3.0 Butylene glycol 2.0 Propylene glycol 2.0 Carboxyvinyl polymer 0.1 ethanol 10.0 Triethanolamine 0.1 Preservatives, micronutrients, trace fragrances and trace water Balance sum 100.0

1-2. Manufacture of nutrition lotion

As shown in the following Table 6, a nutritional lotion containing an extract of Crassus japonica as an active ingredient was prepared according to a conventional method.

ingredient Content (% by weight) Vine Extract 0.1 Wax 4.0 Polysorbate 60 1.5 Sorbitan sesquioleate 0.5 Liquid paraffin 5.0 Squalane 5.0 Caprylic / capric triglyceride 5.0 glycerin 3.0 Butylene glycol 3.0 Propylene glycol 3.0 Carboxyvinyl polymer 0.1 Triethanolamine 0.2 Preservatives, micronutrients, trace fragrances and trace water Balance sum 100.0

1-3. Manufacture of nutrition cream

As shown in Table 7 below, a nutritional cream containing an extract of Crassulaceae as an active ingredient was prepared according to a conventional method.

ingredient Content (% by weight) Vine Extract 0.1 Wax 10.0 Polysorbate 60 1.5 Sorbitan sesquioleate 0.5 Liquid paraffin 10.0 Squalane 5.0 Caprylic / capric triglyceride 5.0 glycerin 5.0 Butylene glycol 3.0 Propylene glycol 3.0 Triethanolamine 0.2 Preservatives, micronutrients, trace fragrances and trace water Balance sum 100.0

1-4. Manufacture of massage cream

As shown in Table 8 below, a massage cream containing an extract of Crassulaceae as an active ingredient was prepared according to a conventional method.

ingredient Content (% by weight) Vine Extract 0.1 Wax 10.0 Polysorbate 60 1.5 Sorbitan sesquioleate 0.8 Liquid paraffin 40.0 Squalane 5.0 Caprylic / capric triglyceride 4.0 glycerin 5.0 Butylene glycol 3.0 Propylene glycol 3.0 Triethanolamine 0.2 Preservatives, micronutrients, trace fragrances and trace water Balance sum 100.0

1-5. Manufacture of packs

As shown in the following Table 9, packs containing Crane Extracts as active ingredients were prepared according to a conventional method.

ingredient Content (% by weight) Vine Extract 0.1 Polyvinyl alcohol 13.0 Sodium carboxymethylcellulose 0.2 Allantoin 0.1 ethanol 5.0 Nonyl phenyl ether 0.3 Preservatives, micronutrients, trace fragrances and trace water Balance sum 100.0

Claims (5)

Inhibit the production of advanced glycation end products and wrinkle, skin elasticity improvement and prevention of skin aging, and a cosmetic composition for improving skin conditions that select at least one from the group consisting of skin regeneration, akebia (Akebia quinata ) as an active ingredient.
The composition for external application for skin according to claim 1, wherein the inhibition of the final glycosylation is performed in fibroblasts of the skin.
A pharmaceutical composition for improving the skin condition selected from the group consisting of skin wrinkles, skin elasticity improvement, skin aging prevention, and skin regeneration by inhibiting the production of a final glycation end product, wherein Akebia quinata ) as an active ingredient.
The cosmetic composition according to claim 1, wherein the cosmetic composition is a solution, suspension, emulsion, paste, gel, cream, lotion, powder, soap, surfactant-containing cleansing agent, oil, powder foundation, Wherein the cosmetic composition is in a form selected from among the following.
4. The composition according to any one of claims 1 to 3, wherein the fruit or branch extract of Angelica keiskei comprises 0.0001 to 15% by weight, based on the total weight of the composition.

Images